Pharmaceutical Strategy Analysis l Report Store l Pharma Intelligence

Asthma and COPD KOL Interview

$599.00

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

Find out more

Datamonitor Schizophrenia KOL Interview 2

$599.00

KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.

February 24, 2016

Find out more

Datamonitor Big Pharma Licensing Trends

$3,000.00

This strategy report focuses on Big Pharma Licensing Trends with company analyses, case studies, therapy area analysis, and deal economics.

February 23, 2016

Find out more

Datamonitor Schizophrenia KOL Interview

$599.00

On key factors effecting treatment: “First of all tolerability, because if the tolerability is not good then there will be no adherence. The second is efficacy, and the third one maybe is also whether the compound is also available as a depot. I think that is a major advantage if a drug, if an antipsychotic, is indeed available as a depot or as a long-acting injection (LAI).”

February 10, 2016

Find out more

Acute Lymphocytic Leukemia KOL Interview

$599.00

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

February 9, 2016

Find out more

Triple Negative Breast Cancer KOL Interview

$599.00

“It [Abraxane] is so easy to give. Women tolerate it so well. It works pretty good, it doesn’t work all the time, it works pretty well, and the patients don’t get so fatigued, they don’t have side effects, they don’t need premeds, and they rarely need to be boosted for white cells decrease. Whereas in the Eribulin, you know they’re gonna be coming back. It’s a pretty easy drug to give. Patients tolerate it fairly well… I use it [Abraxane] as first line and I go back to it. Even if I have somebody that progresses, if they’ve been off of it for a while, I will often even go back to it.”

February 9, 2016

Find out more

Follicular Lymphoma KOL Interview

$599.00

“When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”

February 3, 2016

Find out more

Drug Pricing and Market Access KOL Interview

$599.00

Expensive oncology treatments [PD-1 and upcoming CAR-T therapies] will continue to be covered by large insurers formularies, but access will be restricted according to NCCN guidelines.

February 1, 2016

Find out more

Key Trends in European Market Access

$2,995.00

This strategy report focuses on Key Trends in European Market Access including accelerating access to medicines, health technology assessment and harmonization, developments in health technology assessment, pricing, and reimbursement delays.

January 26, 2016

Find out more

Intersection Between Tech and Pharma KOL Interview

$599.00

Given the rapid change in the healthcare industry over the last few years, it is no surprise that we are starting to see more non-traditional healthcare partnerships, specifically with big tech companies.

January 12, 2016

Find out more

Treatment of VTE – EU KOL Interview

$599.00

This interview with an EU vascular physician explores the dynamics in the 5 major European markets regarding the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 4, 2015

Find out more

Treatment of VTE – US KOL Interview

$599.00

This interview with a US hematologist focuses on the changing dynamics with the introduction of novel/direct oral anticoagulants (NOAC, DOAC) in the treatment of venous thromboembolism (VTE) and prevention of recurrence.

November 2, 2015

Find out more

2015 Jardiance EMPA-REG CVOT Pulse

$599.00

This 5-question survey of 30 primary care physicians and 29 endocrinologists in the United States evaluates the impact of the EMPA-REG cardiovascular outcomes trial (CVOT) of SGLT2 inhibitor Jardiance (Boehringer, LLY).

November 1, 2015

Find out more

Biosimilars Market Access in the US

$2,995.00

This strategy report focuses Biosimilars Market Access in the US including the need for biosimilars, regulatory pathways, substitution and naming policy, legal issues, pricing, reimbursement, and market access.

October 23, 2015

Find out more